Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3000 participants.
Also called NCT06866236
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 3,000 participants
- Sponsor
- Ebima Clifford Okundaye
- Registry
-
NCT06866236
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06866236. Randomized; single masking; primary purpose treatment. Start 2025-10 (anticipated); primary completion 2026-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
- Acronym
- NAD agent
- Condition
- Chronic Kidney Diseases
- Condition
- Acute Kidney Injury
- Condition
- Kidney Failure
- Intervention (Drug)
- QRX-3
- Lead sponsor
- Ebima Clifford Okundaye
Record details
- Record id
cardio:ct-nct06866236- Content hash
f53dd2994a4a40b1cb5431b5549a87008f89063421b7b0acf7aa2163135645ad